PIRCHE is a ground-breaking technology based on computer algorithms to determine HLA matching on the epitope level in solid organ transplantation (SOT) and hematopoietic stem cell transplantation (HSCT) applications. The PIRCHE algorithm precisely calculates the level of allorecognition against foreign tissue, i.e. the ability of an individual organism to distinguish its own cells from those of another. Thus, this technology predicts highly relevant the acceptance or rejection of the new organ or the donated stem cells. In contrast to existing technologies, PIRCHE focuses on the important peptide binding properties of HLA molecules – the indirect pathway of allorecognition. PIRCHE is the first company to provide a patented, reliable HLA epitope matching technology and combines it with a sophisticated user interface to an outstanding web based matching system – the PIRCHE web app. This system is available 24/7, from any computer with Internet access. There is no need to install or maintain any software locally and the web app meets all required standards for data security. The technology is validated in several scientific studies with thousands of patients and is already used by multiple leading clinics and labs in everyday practice. PIRCHE focuses on the SOT and HSCT markets. A series of scientific publications and worldwide patent applications form a solid basis for market entry. Building upon this the company pursues a business strategy to convert its more than 200 academic collaborations into regular customers. In addition to direct marketing to leading clinics and their search laboratories, the company licenses its platform to product and service providers in the clinical laboratory field as well as to donor registries, organ allocation organizations and to the biopharmaceutical industry.